KRSA
Stock Fundamental
Valuation1.3/10
BearishKey Valuation Metric
PE Method: KRSA's market cap is approximately 1.54B with TTM earnings of -670.70M, corresponding to a PE ratio of -229.0. Compared to the Chemical Pharmaceuticals industry average, this valuation may be undervalued.
PS Method: KRSA's market cap is approximately 1.54B with a PS ratio of 6.7. Compared to the Chemical Pharmaceuticals industry average, this valuation may be reasonable.
PEG Method: With a PE of -229.0 and forward PE of -227.9, the PEG ratio comes to 1.00, indicating a reasonable valuation.
Historical Price to Earnings Ratio
Historical data shows that KRSA's P/E reached a peak of about 65.35 on 2024-08-02, and a trough of about -262.11 on 2026-09-11. The current P/E is -228.96, which places it at approximately the 10% percentile of its historical range, indicating a relatively undervalued valuation.
Share Price vs Future Cash Flow Value
KRSA's current stock price is about $31.23, while its Discounted Cash Flow valuation is about $26.64. Based on the Discounted Cash Flow model, the market price represents a price close to its intrinsic value.
Future Growth5.5/10
NeutralEarnings and Revenue Growth Forecasts
KRSA's Revenue moved from about 194.00K (2024) to about 1.02M (2025) in recent actuals. Analyst forecasts include about 855.66K, 894.91K, and 934.17K for the next forecast periods, implying an overall 3-year CAGR of roughly -3.0% versus the latest actual—indicating a fluctuating trend in Revenue..
Future Return on Equity
Analysts predict KRSA's future return on equity (Future ROE) will be about -62.3% over the next three years, lower than the Chemical Pharmaceuticals industry average of -47.4%, indicating its backward position in capital profitability. A higher Future ROE generally reflects stronger expected profitability on shareholder equity, subject to business risk and accounting differences.
Past Performance6.8/10
NeutralRevenue & Expenses Breakdown
KRSA's revenue primarily comes from License Agreement, Revenue from Purchase Agreement, Option Agreement and —. Among these, License Agreement accounts for 48.2%; Revenue from Purchase Agreement for 38.6%, Option Agreement for 13.2% and — for 0.0%. The company's main business is relatively diversified.
Earnings & Revenue
No earnings data
Free Cash Flow vs Earnings Analysis
KRSA's net income is about -1.59M, while free cash flow is about -858.00K, representing a FCF/Earnings ratio of 54.0%. The conversion from earnings to free cash flow is moderate, indicating cash generation is in line with typical conversion patterns for the sector.
Financial Health5.5/10
NeutralDebt to Equity History and Analysis
In 2026-06, total liabilities (Debt) are about 1.84M; total equity (Equity) is about 5.09M. These figures come from the financial health diagnose series (debt / equity). They describe capital structure, not operating earnings.
Balance Sheet
Assets
Liabilities + Equity
Dividends4.0/10
NeutralStability and Growth of Payments
KRSA is not paying a notable dividend in the U.S. market context; detailed stability and growth checks are less relevant until distributions become material.
Dividend Yield vs Market
KRSA's current dividend yield is 0.00%, while the Chemical Pharmaceuticals industry average is around 3.48%. The top 25% of companies in the entire US market have a dividend yield of 4.49%, while the bottom 25% have a yield of 2.56%. In comparison, KRSA is clearly at the bottom of the industry.
Earnings Payout to Shareholders
Earnings coverage: KRSA is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash flow coverage: KRSA is not paying a notable dividend for the US market.
